Comparative study of remimazolam combined with propofol and propofol alone for sedation in hysteroscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079888

Enrollment

Unknown

Registered

2024-01-15

Start date

2024-01-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hysteroscopy

Interventions

RP group:remimazolam + proporfol

P group :proporfol

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1 Patients undergoing hysteroscopy requiring intravenous anaesthesia; 2 ASA 1-2; 3 Age 20-45y; 4 BMI 18-25kg/m2

Exclusion criteria

Exclusion criteria: 1 cardiopulmonary disease; 2 Alcohol abuse, liver and kidney dysfunction; 3 chronic use of benzodiazepines, opioids, antidepressants; 4 anesthetic drug allergy; 5 difficulty in cervical dilatation; 6 difficult airway; 7 patients who are participating in other clinical studies; 8 researchers believe that other reasons are not suitable for clinical researchers

Design outcomes

Primary

Measure	Time frame
mean arterial pressure (MAP);	—

Secondary

Measure	Time frame
SpO2, RR, HR;body move;SE,RE,SPI;	—

Countries

China

Contacts

Public ContactXiaowei Qian

Womens' Hospital, School of Medicine, Zhejiang University

qianxw@zju.edu.cn+86 157 0015 7161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026